Advisers to the U.S. Food and Drug Administration (FDA) on Thursday voted unanimously to replace the original Pfizer and Moderna primary series mRNA COVID-19 vaccines with the bivalent boosters designed to target Omicron variants. The bivalent.
Recent evidence suggests that current bipolarity confers protection against severe disease and death from the XBB.1 variant that is currently dominant in
The FDA s vaccine advisers lent support to the agency s plan to try to simplify future COVID shots, with an aim of having many people get just one dose in the fall.
Many questions remain about next steps for US vaccine policy. But the FDA advisory panel’s hearty endorsement of a single-composition COVID-19 vaccine represents a pivotal step.
Expert panel votes FDA SHOULD give Moderna s COVID-19 vaccine emergency approval amid hopes the U.S will soon have a second shot to help get 20 million Americans vaccinated by the end of 2020
A panel of FDA experts voted that the agency should approve Moderna s coronavirus vaccine and recommend whether the shot should be approved
With their endorsement, Moderna s shot will almost certainly get emergency approval tonight or tomorrow
Two people in Moderna s trial had severe allergic reactions: one who got a placebo, and a vaccine recipient who had anaphylactic shock 63 days later
Moderna determined neither were linked to the shot, and allergic reactions are generally immediate, not months later